Cantex Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Weston FL United States (2013)

Organization Overview

First Clinical Trial
2013
NCT00457951
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cantex Pharmaceuticals | Cantex Pharmaceuticals Inc. | Cantex Pharmaceuticals. Inc. | ParinGenix Inc | ParinGenix Inc, Weston FL

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Intestinal Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 1)

Protein-Losing Enteropathies (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 18